IPH Innate Pharma SA Class A

Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update

Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Tuesday, May 14, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2024.

Participants during the call will be:

  • Hervé Brailly, Chief Executive Officer
  • Sonia Quaratino, Executive Vice President, Chief Medical Officer
  • Yannis Morel, Executive Vice President, Chief Operating Officer
  • Frédéric Lombard, Senior Vice President, Chief Financial Officer
  • Arvind Sood, Executive Vice President, President of US Operations

Details for the Virtual Event

The live webcast will be available at the following link:

Participants may also join via telephone using the following registration link:

This information can also be found on the Investors section of the Innate Pharma website, . A replay of the webcast will be available on the Company website for 90 days following the event.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform.

Innate’s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET® multi-specific NK cell engagers to address multiple tumor types.

Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at and follow us on and .

Information about Innate Pharma shares

ISIN code

FR0010331421

Ticker code

Euronext: IPH Nasdaq: IPHA

LEI

9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

EN
07/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Innate Pharma SA Class A

 PRESS RELEASE

Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate’s drug candidates have been accepted for the European Association of Hematology (EHA) 2024 Congress, taking place June 13-16, 2024 in Madrid, Spain. Two abstracts are related to SAR443579 (IPH6101), an investigational trifunctional anti-CD123 NKp46xCD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi and currently being evaluated as a monotherapy in a Sanofi-sponsored Phas...

 PRESS RELEASE

Innate Pharma partage les abstracts sélectionnés pour le congrès 2024 ...

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd’hui que quatre abstracts concernant des candidats-médicaments d’Innate ont été sélectionnés pour le congrès annuel de l’EHA (European Hematology Association), qui se tiendra du 13 au 16 juin 2024 à Madrid : Deux abstracts concernent SAR443579 (IPH6101), un NK Cell Engager trifonctionnel engageant les récepteurs NKp46/CD16 et ciblant CD123, issu d’une collaboration entre Innate Pharma et Sanofi, et actuellement évalué en monothérapie d...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir

Innate Pharma : No surprises in Q1 results, pending the ASCO

>Financial visibility out to end-2025 - This morning, Innate Pharma published its top line and cash position for Q1 2024. The group does not yet generate recurring revenues, with revenues over the period largely stemming from the recognition of payments received from its partnerships with AstraZeneca and Sanofi coming in at € 6.6m (vs € 26m in 2023). The cash position at end-March 2024 was € 114m vs € 102.3m at end-December 2023 (without factoring in the € 4m still t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch